Akebia Therapeutics Stock News

AQR Capital Management LLC lessened its position in Akebia Therapeutics, Inc. (NASDAQ:AKBA) by 64.3% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 14,019 shares of the biopharmaceutical companys stock after selling 25,229 shares during the quarter. AQR Capital Management []

CAMBRIDGE, Mass., Nov. 24, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today

The trading price of Akebia Therapeutics Inc. (NASDAQ:AKBA) floating lower at last check on Tuesday, November 23, closing at $2.66, 0.00% lower than its previous close. >> 7 Top Picks for the Post-Pandemic Economy

In todays recent session, 0.98 million shares of the Akebia Therapeutics Inc. (NASDAQ:AKBA) have been traded, and its beta is 1.56. Most recently the companys share price was $2.70, and it changed around -$0.08 or -2.70% from the last close, which brings the market valuation of the company to $481.69M. AKBA at last check was Akebia Therapeutics Inc. (NASDAQ: AKBA) Stock: Does It Have The Potential To Rise? Read More »

Akebia Therapeutics Inc. (NASDAQ:AKBA)’s traded shares stood at 0.94 million during the latest session, with the company’s beta value hitting 1.56. At the last check today, the stock’s price was $2.73, to imply a decrease of -2.32% or -$0.07 in intraday trading. The AKBA share’s 52-week high remains $5.14, putting it -88.28% down since that … Akebia Therapeutics Inc. (NASDAQ: AKBA) Has Fallen -88.28% From Its Highs, What Comes Next? Read More »

Northern Trust Corp grew its holdings in shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA) by 2.1% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,690,808 shares of the biopharmaceutical companys stock after acquiring an additional 34,569 shares during the quarter. Northern Trust Corp owned 0.97% []

Akebia Therapeutics (NASDAQ:AKBA) had its price target boosted by HC Wainwright from $6.00 to $10.00 in a research note issued to investors on Thursday, Analyst Price Targets reports. The brokerage currently has a buy rating on the biopharmaceutical companys stock. Separately, Zacks Investment Research cut shares of Akebia Therapeutics from a buy rating to a []

Marshall Wace LLP acquired a new stake in Akebia Therapeutics, Inc. (NASDAQ:AKBA) in the 2nd quarter, Holdings Channel reports. The institutional investor acquired 4,109,589 shares of the biopharmaceutical companys stock, valued at approximately $15,575,000. A number of other hedge funds also recently made changes to their positions in AKBA. Walleye Capital LLC raised its holdings []

Akebia Therapeutics, Inc. (AKBA) CEO John Butler on Q3 2021 Results - Earnings Call Transcript

Unwilling to wait for catalysts, some investors threw these small-cap stocks into the garbage bin. But that doesn't mean they won't succeed.

CAMBRIDGE, Mass. , Sept. 1, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today

Akebia Therapeutics, Inc. (AKBA) CEO John Butler on Q2 2021 Results - Earnings Call Transcript

Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -70.00% and -11.93%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Are these biotech penny stocks worth investing in or not? The post 3 Hot Biotech Penny Stocks to Watch With High Volume in 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | Pen

Akebia Therapeutics (AKBA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.